Monocyte activation by circulating fibronectin fragments in HIV-1-infected patients.
To identify signals that can alter leukocyte function in patients receiving highly active antiretroviral therapy (HAART), we analyzed single blood samples from 74 HIV-1-infected patients and additional blood was collected at 90-day intervals from 51 HIV-1-infected patients over a 516 +/- 172 (mean +/- SD) day interval. Despite the absence of circulating immune complexes and normalization of phagocytic function, compared with controls, the fraction of patients' monocytes expressing CD49e and CD62L was decreased and expression of CD11b and CD86 increased. Plasma from 63% of patients but none from normal controls contained 110-120 kDa fibronectin fragments (FNf). Presence of FNf did not reflect poor adherence to therapy. Addition of FNf to normal donor blood in vitro replicated changes in monocyte CD49e, CD62L, CD11b, and CD86 seen in vivo. FNf also induced monocytes to release a serine proteinase, nominally identified as proteinase-3, that hydrolyzed cell surface CD49e. alpha(1)-Antitrypsin blocked FNf-induced shedding of CD49e in a dose-dependent manner. Plasma with a normal frequency of CD49e(+) monocytes contained antiproteases that partially blocked FNf-induced monocyte CD49e shedding, whereas plasma from patients with a low frequency of CD49e(+) monocytes did not block this effect of FNf. Electrophoretic analyses of plasma from the latter group of patients suggested that a significant fraction of their alpha(1)-antitrypsin was tied up in high molecular mass complexes. These results suggest that monocyte behavior in HIV-1-infected patients may be influenced by FNf and the ratio of protease and antiproteases in the cells' microenvironment.
Trial
JoAnn
J
Research Center for AIDS and HIV Infections, Immunology Research Laboratory, Veterans Affairs Medical Center, and Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Rubio
Jose A
JA
Birdsall
Holly H
HH
Rodriguez-Barradas
Maria
M
Rossen
Roger D
RD
D015703:Antigens, CD / Q000096:biosynthesis / Q000235:genetics; D023241:Antiretroviral Therapy, Highly Active; D051940:B7-2 Antigen; D039481:CD11b Antigen / Q000096:biosynthesis / Q000235:genetics; D005353:Fibronectins / Q000737:chemistry*; D005786:Gene Expression Regulation / Q000187:drug effects; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy; D015497:HIV-1; D006801:Humans; D016130:Immunophenotyping; D039482:Integrin alpha5 / Q000096:biosynthesis / Q000235:genetics; D019041:L-Selectin / Q000096:biosynthesis / Q000235:genetics; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000235:genetics; D053146:Myeloblastin; D010446:Peptide Fragments / Q000097:blood* / Q000494:pharmacology / Q000502:physiology; D010587:Phagocytosis; D012697:Serine Endopeptidases / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology; D000515:alpha 1-Antitrypsin / Q000494:pharmacology
D015703:Antigens, CD; D051940:B7-2 Antigen; D039481:CD11b Antigen; C497964:CD86 protein, human; D005353:Fibronectins; D039482:Integrin alpha5; D008562:Membrane Glycoproteins; D010446:Peptide Fragments; D015842:Serine Proteinase Inhibitors; D000515:alpha 1-Antitrypsin; D019041:L-Selectin; D012697:Serine Endopeptidases; D053146:Myeloblastin